NCT05839288已完成不适用
Pyrotinib Plus Trastuzumab and Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 161
- 试验地点
- 1
- 主要终点
- progression-free survival (PFS)
研究概览
简要总结
To evaluate the patterns and treatment outcomes of pyrotinib plus trastuzumab and chemotherapy in the real world.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •woman, age > 18 years old
- •diagnosed with HER2 +Metastatic Breast Cancer
- •received pyrotinib plus trastuzumab and chemotherapy for at least one cycle, starting from 2018.07-2022.09
- •available medical history
排除标准
- •medical history was incomplete
结局指标
主要结局
progression-free survival (PFS)
时间窗: 6 weeks
Progression free survival
次要结局
- Adverse events(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.Colorectal CancerNCT03843749Shanghai Changzheng Hospital30
Unknown
不适用
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBCHER2-positive Breast CancerMetastatic Breast CancerNCT04609540Shandong Cancer Hospital and Institute200
进行中（未招募）
2 期
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerBreast Cancer InvasiveNCT04398914Shanghai Jiao Tong University School of Medicine216
招募中
1 期
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical StudyBreast CancerNCT06770296The First Affiliated Hospital with Nanjing Medical University200
尚未招募
2 期
A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast CancerHER2-positive Recurrent/Metastatic Breast CancerNCT05621434Fujian Medical University63